Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is transitioning from a development-stage biotechnology company to a commercial-stage entity with the launch of LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma. The company's progress highlights its strategy of building a diversified portfolio to address significant unmet medical needs, with implications for patients and the broader oncology and critical-care markets.
LYMPHIR, approved by the U.S. Food and Drug Administration in August 2024, is designed for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The drug's commercial launch in December 2025 generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This revenue marks a significant milestone for Citius, providing a commercial foundation and validating its ability to bring products to market. The company also reported that payer coverage represents nearly 100% of covered commercial lives, and 83% of targeted accounts had achieved formulary inclusion or were under active review as of May 2026. Additionally, an initial shipment of LYMPHIR to Europe in April 2026 signals international expansion potential.
The importance of LYMPHIR extends beyond initial sales. Citius is exploring its use in other oncology settings, with investigator-initiated studies evaluating the drug in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to CD19-directed CAR-T therapy for high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting broader applications that could expand its market reach and benefit more patients.
Beyond LYMPHIR, Citius' late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients who depend on central venous catheters. Mino-Lok met the primary and secondary endpoints of its pivotal Phase 3 trial, and it has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. With no FDA-approved therapies specifically indicated for salvaging infected central venous catheters, Mino-Lok could address a critical need and reduce complications like pneumothorax, arterial puncture, and catheter misplacement associated with catheter removal and reinsertion. Citius estimates worldwide sales potential of approximately $1.8 billion for this product.
Another promising candidate is Halo-Lido (CITI-002), a topical formulation combining halobetasol and lidocaine for symptomatic relief of hemorrhoids. Approximately 10 million people in the United States report hemorrhoid symptoms annually, yet there are no FDA-approved prescription products for this indication. If approved, Halo-Lido could become the first such product, offering a significant commercial opportunity. The company completed a Phase 2b study in 2023 and has engaged with the FDA to determine next steps.
Citius is also developing a stem cell platform using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. While additional studies are needed, this program could address a condition with high mortality and few effective treatments.
The company's leadership brings extensive experience in pharmaceutical development and commercialization. Leonard Mazur, CEO, has decades of industry experience, and Myron Holubiak, Executive Vice Chairman, previously served as president of Roche Laboratories. This expertise is crucial as Citius navigates regulatory pathways and commercial expansion. With LYMPHIR generating revenue and multiple pipeline candidates advancing, Citius is positioned for potential growth, though investors should consider the risks inherent in drug development and commercialization.
